HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
VREX
Varex Imaging Corporation
VREX's fundamentals are strong, but it looks expensive: trading at 35x earnings, above its usual 31x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
VREX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Under pressure | |
| Stable |
VREX's profitability is currently healthy, and its revenue and balance sheet are stable, but its cash flow is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
VREX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 18x | $9.16 | -50% |
| Forward | 20x | $18.27 | — |
| Fair | 31x | $16.23 | -11% |
| Current | 35x | $18.27 | — |
| Expensive | 69x | $35.92 | +97% |
Historical ranges are pointers, not guarantees.
VREX's PE is in its fair range at 35x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
VREX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect VREX's earnings to grow, with its revenue and profitability holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
VREX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.91 | +75% |
| Q2 2026 | $0.52 | +$3.73 |
| Q1 2026 | -$2.00 | -$0.97 |
| Q4 2025 | -$1.64 | -$0.47 |
| Q3 2025 | -$1.70 | -$0.53 |
| Q2 2025 | -$3.21 | -534% |
| Q1 2025 | -$1.03 | -212% |
| Q4 2024 | -$1.17 | -218% |
| Q3 2024 | -$1.17 | -208% |
VREX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over VREX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
VREX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $210.5M | +3.7% |
| Q1 2026 | $216M | +1.5% |
| Q4 2025 | $209.6M | +4.9% |
| Q3 2025 | $228.9M | +11% |
| Q2 2025 | $203M | -2.9% |
| Q1 2025 | $212.9M | +3.2% |
| Q4 2024 | $199.8M | +5.2% |
| Q3 2024 | $205.7M | -9.5% |
VREX's revenue has grown year over year for four quarters in a row: $211M last quarter, up 3.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 11% | +51 points |
| Q1 2026 | 6.7% | -3.7 points |
| Q4 2025 | 7.3% | +1.7 points |
| Q3 2025 | 8.6% | +3.3 points |
| Q2 2025 | -40% | -44 points |
| Q1 2025 | 10% | +6.7 points |
| Q4 2024 | 5.6% | +3.4 points |
| Q3 2024 | 5.3% | -5.4 points |
VREX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over VREX on cash generation, producing positive trailing cash flow while its opponent burns cash.
VREX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $12M | +757% |
| Q1 2026 | -$7.7M | -179% |
| Q4 2025 | -$26.8M | -606% |
| Q3 2025 | $2.3M | -88% |
| Q2 2025 | $1.4M | -58% |
| Q1 2025 | $9.8M | +$12.5M |
| Q4 2024 | $5.3M | +$5.4M |
| Q3 2024 | $19.9M | -52% |
VREX's free cash flow was −$20M over the past year, against $36M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over VREX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
VREX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.4% | +600K shares |
| 1 year | +2.7% | +1.1M shares |
| 3 years | -15% | -7.8M shares |
| 5 years | +3.1% | +1.3M shares |
| Available history | +10% | +4M shares |
VREX has 43M diluted shares, up 2.7% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over VREX on leverage, with a lower net debt burden relative to earnings.
VREX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 2.5x | Moderate |
| Q4 2025 | 75.2x | High |
| Q1 2025 | 4.5x | High |
| Q4 2024 | 5.7x | High |
| Q3 2024 | 4.4x | High |
| Q2 2024 | 3.6x | Elevated |
| Q1 2024 | 3.2x | Elevated |
| Q4 2023 | 3.0x | Moderate |
VREX's net debt is about 2.5 years of its operating earnings (EBITDA), down from 4.3 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
VREX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.5 | Overbought |
| Stochastic | 65.8 | Neutral |
VREX's weekly RSI is 75 (overbought) and its Stochastic is 66 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
VREX PE vs Healthcare Sector
| Metric | VREX | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 26x | 36% above |
| PE % | 65 | 29 | 36 pts above |
VREX is trading at 35x earnings, a 36% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
VREX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.4 | 0.8% below |
| 20 week MA | $16.3 | 12% above |
| 50 week MA | $13.5 | 35% above |
| 100 week MA | $12.1 | 51% above |
| 200 week MA | $14.9 | 23% above |
VREX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
VREX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.3 | $16.3 | -46% |
| 2021 | $16.3 | $31.8 | +96% |
| 2022 | $31.8 | $19.8 | -38% |
| 2023 | $19.8 | $20.5 | +3.5% |
| 2024 | $20.5 | $14.8 | -28% |
| 2025 | $14.8 | $11.8 | -20% |
| 2026 YTD | $11.8 | $18.3 | +54% |
VREX has the edge over HIMS on returns for 2026, with the stronger performance.